Loading
companiesCompany
Nuvation Bio
Nuvation Bio is a United States-based biotechnology company running 6 late-stage cancer trials of Taletrectinib, AB-106 and NUV-1511 in non-small-cell lung cancer, HR-positive / HER2-negative breast cancer and prostate cancer.
Also called: Nuvation Bio Inc.
Overview
Nuvation Bio, based in New York, NY, the United States, is a biotechnology company. A global oncology company developing therapies for difficult-to-treat cancers; its taletrectinib (IBTROZI) is FDA-approved for ROS1-positive non-small cell lung cancer. On ClinicalTrials.gov it is the lead sponsor of 6 recruiting or active phase 2 and phase 3 interventional cancer trials (3 in phase 3), testing Taletrectinib, AB-106, NUV-1511 and safusidenib in non-small-cell lung cancer, HR-positive / HER2-negative breast cancer, prostate cancer, pancreatic ductal adenocarcinoma and ovarian cancer. The largest, NCT06334432 (Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumours), plans to enrol 466 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.
Headquarters
New York, NY, US
Scorecard
All companies#212of 1244 companies, score 25
- approved products +6
- phase 3 +3
- phase 1/2 +1
- targets +4
- modalities +2
- regions +3
- registry trials +6
1 approved, 1 in phase 3, 1 earlier, 2 targets, 9 registry studies. Formula on the scorecards page.
Type
Stage
Public
Website
Founded
2018
Phase 3small molecule inhibitor
Safusidenib is an experimental small molecule inhibitor from Nuvation Bio in phase 3 trials for glioma & glioblastoma, aimed at IDH1 / IDH2.
Phase 2Small-molecule inhibitor
NUV-1511 is a small-molecule inhibitor from Nuvation Bio Inc., in registered phase 2 trials for prostate cancer, pancreatic ductal adenocarcinoma, ovarian cancer.
ApprovedSmall-molecule ROS1 TKI (next generation, CNS-penetrant)
Taletrectinib · Ibtrozi
A ROS1 lung-cancer pill approved in 2025 that works in the brain and after crizotinib, with fewer dizziness-type side effects than repotrectinib.
Similar pages
- TrialA Study of DS-1001b in Patients With Chemotherapy- and Radiotherapy-Naive IDH1 Mutated WHO Grade II Glioma
Shares Safusidenib, Glioma & glioblastoma.
- TrialBasket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangeme
Shares ROS1-positive non-small-cell lung cancer, Ovarian cancer, Non-small-cell lung cancer.
- TrialA Study of XZP-5955 Tablets in Patients With NTRK or ROS1 Fusion Positive Locally Advanced or Metastatic Solid Tumors
Shares ROS1-positive non-small-cell lung cancer, Non-small-cell lung cancer.
- TrialNeoadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small Cell Lung Cancer
Shares ROS1-positive non-small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)
Shares ROS1-positive non-small-cell lung cancer, Non-small-cell lung cancer.
- PersonRobert C. Doebele
Shares ROS1-positive non-small-cell lung cancer, Non-small-cell lung cancer.
- CancerAstrocytoma, IDH-mutant (grades 2 to 4)
Shares SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance), Safusidenib, Glioma & glioblastoma.
- TrialA Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases
Shares ROS1-positive non-small-cell lung cancer, Non-small-cell lung cancer.
cancers
drugs
Phase 2Small-molecule inhibitor
Phase 3small molecule inhibitor
ApprovedSmall-molecule ROS1 TKI (next generation, CNS-penetrant)
Taletrectinib · Ibtrozi
trials
A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer PatientsA Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion GenePhase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid TumorsSIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC